Search results
Showing 421 to 435 of 855 results for end of life
Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)
Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.
Intramedullary distraction for upper limb lengthening (HTG621)
Evidence-based recommendations on intramedullary distraction for upper limb lengthening in children, young people and adults. This involves surgically inserting a metal lengthening device in the shorter arm.
View recommendations for HTG621Show all sections
Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.
maintaining high-flow nasal oxygen at home for patients who wish their end of life care to occur at home. Source guidance details Comes...
Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)
Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
Tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis (HTG648)
Evidence-based recommendations on tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis. This involves inserting a catheter under the skin in the abdomen to drain excess fluid when needed, at home or in community care. The aim is to reduce the need for hospital admissions and improve quality of life.
View recommendations for HTG648Show all sections
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)
Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.
secretions:- In people considered to be in the last few hours and days of life, are antisecretory anti-muscarinic drugs (used alongside...
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)
Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults.
Endoscopic injection of bulking agents for gastro-oesophageal reflux disease (HTG28)
Evidence-based recommendations on endoscopic injection of bulking agents for gastro-oesophageal reflux disease. This involves injecting a filler into the junction using a catheter to make the entry to the stomach narrower, so that the contents of the stomach cannot pass back.
View recommendations for HTG28Show all sections
Sections for HTG28
Endoluminal gastroplication for gastro-oesophageal reflux disease (HTG661)
Evidence-based recommendations on endoluminal gastroplication for gastro-oesophageal reflux disease. This involves an endoscopic fastening device being inserted through the mouth and into the stomach, along with an endoscope for constant visualisation. The device is used to attach the fundus to the anterior and left lateral wall of the distal oesophagus slightly above the oesophagogastric junction.
View recommendations for HTG661Show all sections
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults.
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.
Evidence-based recommendations on collagen paste for closing an anal fistula in adults. This involves using the paste to fill the fistula to seal it. The aim is to encourage healing.
View recommendations for HTG512Show all sections